Coronavirus (COVID-19) Vaccine Update
Click here to learn more.
For information about COVID-19 or to view additional resources, please
Primary objective:To evaluate the overall survival of fruquintinib plus BSC compared to placebo plus BSC in subjects with refractory mCRC.
Hutchison MediPharma, Ltd.
George Kim, MD